{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:37:26Z","timestamp":1772764646165,"version":"3.50.1"},"reference-count":48,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>The limitations caused by the spread of the SARS-CoV2 virus have had repercussions on the voluntary termination of pregnancy. During the pandemic, Italy issued updated guidelines regarding voluntary termination of pregnancy by means of mifepristone and prostaglandin. This included news concerning the time limit and location in which this procedure could be accessed: updates partially recognize women\u2019s needs, and they are into line with the European parliament\u2019s recent exhortations. However, these updates do not change the previously provided responsibilities that lie with doctors. This article aimed to compare regulations concerning medical abortion in Italy and other countries, with a focus on recent Italian updates in the context of pandemic.<\/jats:p>","DOI":"10.3390\/ijerph182212043","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T02:42:28Z","timestamp":1637116948000},"page":"12043","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacological Abortion in a Pandemic: An Italian Medico-Legal Perspective"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4919-7070","authenticated-orcid":false,"given":"Clara","family":"Cestonaro","sequence":"first","affiliation":[{"name":"Legal Medicine, University of Padua, 35121 Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Aprile","sequence":"additional","affiliation":[{"name":"Legal Medicine, University of Padua, 35121 Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8784-8463","authenticated-orcid":false,"given":"Matteo","family":"Bolcato","sequence":"additional","affiliation":[{"name":"Legal Medicine, University of Padua, 35121 Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Legal Medicine, University of Padua, 35121 Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9666-2636","authenticated-orcid":false,"given":"Alessandro","family":"Feola","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Campania \u201cLuigi Vanvitelli\u201d, Via Luciano Armanni 5, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7279-3693","authenticated-orcid":false,"given":"Giulio","family":"Di Mizio","sequence":"additional","affiliation":[{"name":"Forensic Medicine, Department of Law, \u201cMagna Graecia\u201d University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Bolcato, M., Trabucco Aurilio, M., Di Mizio, G., Piccioni, A., Feola, A., Bonsignore, A., Tettamanti, C., Ciliberti, R., Rodriguez, D., and Aprile, A. (2021). The Difficult Balance between Ensuring the Right of Nursing Home Residents to Communication and Their Safety. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18052484"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bolcato, M., Trabucco Aurilio, M., Aprile, A., Di Mizio, G., Della Pietra, B., and Feola, A. (2021). Take-Home Messages from the COVID-19 Pandemic: Strengths and Pitfalls of the Italian National Health Service from a Medico-Legal Point of View. Healthcare, 9.","DOI":"10.3390\/healthcare9010017"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Shander, A., Mesrobian, J., Weiss, J., and Javidroozi, M. (2021). Deploying Healthcare Providers during COVID-19 Pandemic. Disaster Med. Public Health Prep., 1\u201313.","DOI":"10.1017\/dmp.2021.116"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1067\/mob.2000.107948","article-title":"Medical abortion regimens: Historical context and overview","volume":"183","author":"Creinin","year":"2000","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1552-6909.1994.tb01921.x","article-title":"RU 486: An alternative to surgical abortion","volume":"23","author":"Donaldson","year":"1994","journal-title":"J. Obstet. Gynecol. Neonatal Nurs."},{"key":"ref_6","unstructured":"National Center for Biotechnology Information (2021, August 02). PubChem Compound Summary for CID 55245, Mifepristone, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Mifepristone."},{"key":"ref_7","first-page":"707","article-title":"Mifepristone","volume":"35","author":"DeHart","year":"2001","journal-title":"Ann Pharm."},{"key":"ref_8","first-page":"191","article-title":"Analysis of severe adverse events related to the use of mifepristone as an abortifacient","volume":"40","author":"Gary","year":"2006","journal-title":"Ann Pharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1748-720X.1992.tb01189.x","article-title":"\u201cInducing a miscarriage\u201d: Women-centered perspectives on RU 486\/prostaglandin as an early abortion method","volume":"20","author":"Berer","year":"1992","journal-title":"Law Med. Health Care"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0091-2182(96)00154-1","article-title":"Pregnancy interruption using mifepristone (RU-486). A new choice for women in the USA","volume":"42","author":"Mackenzie","year":"1997","journal-title":"J. Nurse Midwifery"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.contraception.2009.08.004","article-title":"Mifepristone: Ten years later","volume":"81","author":"Schaff","year":"2010","journal-title":"Contraception"},{"key":"ref_12","first-page":"7","article-title":"The state of medical abortion in Europe today","volume":"59","author":"Bracken","year":"2005","journal-title":"Entre Nous Eur. Mag. Sex. Reprod. Health"},{"key":"ref_13","unstructured":"British Medical Association (2021, August 02). Decriminalisation of abortion: A Discussion Paper from the BMA. Available online: https:\/\/www.bma.org.uk\/media\/1142\/bma-paper-on-the-decriminalisation-of-abortion-february-2017.pdf."},{"key":"ref_14","unstructured":"Royal College of Obstetricians and Gynaecologists (2021, August 02). The Care of Women Requesting Induced Abortion Evidence-Based Clinical Guideline Number 7. Available online: https:\/\/www.rcog.org.uk\/globalassets\/documents\/guidelines\/abortion-guideline_web_1.pdf."},{"key":"ref_15","unstructured":"Ministe\u00e8re des Solidarit\u00e9s et de la Sant\u00e9 (2021, August 02). Avortement: Quels sont les d\u00e9lais \u00e0 Resoecter Pour Avorter?, Available online: https:\/\/ivg.gouv.fr\/avortement-quels-sont-les-delais-a-respecter-pour-avorter.html."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2307\/3097714","article-title":"Mifepristone for early medical abortion: Experiences in France, Great Britain and Sweden","volume":"34","author":"Jones","year":"2002","journal-title":"Perspect Sex. Reprod. Health"},{"key":"ref_17","unstructured":"(2000). Mifepristone for termination of early pregnancy. FDA Consum., 34, 7."},{"key":"ref_18","unstructured":"U.S. Food & Drug Administration (2021, August 02). Mifeprex (Mifepristone) Information, Available online: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/mifeprex-mifepristone-information."},{"key":"ref_19","unstructured":"Royal Australian and New Zealand College of Obstetricians and Gynaecologists (2021, August 02). The Use of Mifepristone for Medical Abortion. Available online: https:\/\/ranzcog.edu.au\/RANZCOG_SITE\/media\/RANZCOG-MEDIA\/Women%27s%20Health\/Statement%20and%20guidelines\/Clinical%20-%20Gynaecology\/Use-of-mifepristone-for-medical-abortion(C-Gyn-21)Review-March-2019_2.pdf?ext=.pdf."},{"key":"ref_20","unstructured":"World Health Organization (2021, August 02). Clinical Practice Handbook for Safe Abortion. Available online: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/97415\/9789241548717_eng.pdf?sequence=1."},{"key":"ref_21","unstructured":"World Health Organization (2021, August 02). Medical Management of Abortion. Available online: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/278968\/9789241550406-eng.pdf."},{"key":"ref_22","first-page":"823","article-title":"Aborto farmacologico ed emergenza sanitaria da COVID-19","volume":"4","author":"Iadicicco","year":"2020","journal-title":"Quad. Cost. Riv. Ital. Di Dirit. Cost."},{"key":"ref_23","unstructured":"Ministero della Salute (2021, August 02). Interruzione volontaria di gravidanza con mifepristone e prostaglandine Anni 2010\u20132011, Available online: https:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_1938_allegato.pdf."},{"key":"ref_24","unstructured":"Agenzia Italiana del Farmaco (2021, August 02). Delibera n. 14 del 30 luglio 2009, Available online: http:\/\/www.quotidianosanita.it\/allegati\/allegato8228279.pdf."},{"key":"ref_25","unstructured":"(2021, August 02). Legge 22 Maggio 1978, n.194. Norme per la Tutela Sociale della Maternit\u00e0 e Sull\u2019interruzione Volontaria di Gravidanza. Gazzetta Ufficiale della Repubblica Italiana Numero 140. Available online: https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=1978-05-22&atto.codiceRedazionale=078U0194&elenco30giorni=false."},{"key":"ref_26","unstructured":"(2021, August 02). Autorizzazione All\u2019immissione in Commercio del Medicinale per uso umano \u201cMifegyne\u201d. Estratto Determinazione n. 1460 del 24 Novembre 2009. Gazzetta Ufficiale della Repubblica Italiana. Supplemento Ordinario n. 229 alla Gazzetta Ufficiale. Serie Generale n. 286. Available online: https:\/\/www.gazzettaufficiale.it\/eli\/gu\/2009\/12\/09\/286\/so\/229\/sg\/pdf."},{"key":"ref_27","unstructured":"Ministero della Salute (2021, August 02). Linee di Indirizzo sulla Interruzione Volontaria di Gravidanza con Mifepristone e Prostaglandine, Available online: https:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_1302_allegato.pdf."},{"key":"ref_28","unstructured":"Ministero della Salute (2021, August 02). Consiglio Superiore di Sanit\u00e0. Segreteria Generale. Sessione XLV. Seduta del 18 marzo 2004. Sezione V, Available online: https:\/\/www.salute.gov.it\/imgs\/C_17_pagineAree_1782_listaFile_itemName_1_file.pdf."},{"key":"ref_29","unstructured":"Ministero della Salute (2021, August 02). Consiglio Superiore di Sanit\u00e0. Sessione XLV. Seduta del 20 dicembre 2005. Assemblea Generale, Available online: https:\/\/www.salute.gov.it\/imgs\/C_17_pagineAree_1782_listaFile_itemName_2_file.pdf."},{"key":"ref_30","unstructured":"Ministero della Salute (2021, August 02). Dipartimento della Qualit\u00e0. Notifica del Parere Espresso in Data 18 Marzo 2010 dal Consiglio Superiore di in Materia di Farmaco RU-486, Available online: https:\/\/www.salute.gov.it\/imgs\/C_17_pagineAree_1782_listaFile_itemName_3_file.pdf."},{"key":"ref_31","unstructured":"Ministero della Salute (2021, August 02). Relazione del Ministro della Salute sulla Attuazione della Legge Contenente Norme per la Tutela Sociale della Maternit\u00e0 e per L\u2019Interruzione Volontaria di Gravidanza (legge 194\/78). Dati Definitivi 2017, Available online: https:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_2807_allegato.pdf."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1363\/psrh.12139","article-title":"COVID-19 Abortion Bans and Their Implications for Public Health","volume":"52","author":"Jones","year":"2020","journal-title":"Perspect Sex. Reprod. Health"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"lsaa013","DOI":"10.1093\/jlb\/lsaa013","article-title":"The legal and medical necessity of abortion care amid the COVID-19 pandemic","volume":"7","author":"Donley","year":"2020","journal-title":"J. Law Biosci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1056\/NEJMp2008006","article-title":"Abortion during the COVID-19 Pandemic\u2014Ensuring Access to an Essential Health Service","volume":"382","author":"Bayefsky","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"American College of Obstetricians and Gynecologists\u2019 Committee on Practice Bulletins\u2014Gynecology, Society of Family Planning (2020). Medication Abortion Up to 70 Days of Gestation: ACOG Practice Bulletin, Number 225. Obs. Gynecol., 136, e31\u2013e47.","DOI":"10.1097\/AOG.0000000000004082"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1136\/bmjsrh-2020-200724","article-title":"Abortion regulation in Europe in the era of COVID-19: A spectrum of policy responses","volume":"47","author":"Moreau","year":"2021","journal-title":"BMJ Sex. Reprod. Health"},{"key":"ref_37","unstructured":"Ministe\u00e8re des Solidarit\u00e9s et de la Sant\u00e9 (2021, August 02). IVG et Mesures Exceptionnelles en P\u00e9riode COVID-19, Available online: https:\/\/ivg.gouv.fr\/ivg-et-mesures-exceptionnelles-en-periode-covid-19.html."},{"key":"ref_38","unstructured":"R\u00e9publique Francaise L\u00e9gifrance (2021, August 02). Arret\u00e9 du 7 Novembre 2020 Modifiant L\u2019arret\u00e9 du 10 Juillet 2020 Prescrivant les Mesures D\u2019organisation et de Fonctionnement du Syst\u00e8me de Sant\u00e9 N\u00e9cessaires pour Faire Face \u00e0 L\u00ec\u00e9pid\u00e9mie de COVID-19 dans le cadre de L\u2019\u00e9\u00e9tat D\u2019urgence Sanitaire. Available online: https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000042506409."},{"key":"ref_39","unstructured":"Gov.UK (2021, August 02). Closed Consultation Home Use of Both Pills for Early Medical Abortion Up to 10 Weeks Gestation, Available online: https:\/\/www.gov.uk\/government\/consultations\/home-use-of-both-pills-for-early-medical-abortion\/home-use-of-both-pills-for-early-medical-abortion-up-to-10-weeks-gestation."},{"key":"ref_40","unstructured":"Royal College of Obstetricians and Gynaecologists (2021, August 02). Coronavirus (COVID-19) Infection and Abortion Care Information for Healthcare Professionals. Available online: https:\/\/www.rcog.org.uk\/globalassets\/documents\/guidelines\/2020-07-31-coronavirus-covid-19-infection-and-abortion-care.pdf."},{"key":"ref_41","unstructured":"Ministero della Salute (2021, August 02). Trasmissione \u201cLinee di Indirizzo per la Rimodulazione dell\u2019attivit\u00e0 Programmata Differibile in Corso di Emergenza da COVID-19\u201d, Available online: http:\/\/www.quotidianosanita.it\/allegati\/allegato5922122.pdf."},{"key":"ref_42","unstructured":"Ministero della Salute (2021, August 02). Chiarimenti Rif. Linee di Indirizzo per la Rimodulazione Dell\u2019attivit\u00e0 Programmata Differibile in Corso di Emergenza da COVID-19, Available online: https:\/\/www.sicp.it\/wp-content\/uploads\/2020\/04\/Min-Sal_circolare-chiarimenti-rimodulaz-attivit\u00e0-sanitaria-differibile_30-mar-20.pdf."},{"key":"ref_43","unstructured":"(2021, August 02). Ministero della Salute Consiglio Superiore di Sanit\u00e0 Sessione LII Seduta Straordinaria del 4 Agosto 2020, Available online: https:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_3039_allegato.pdf."},{"key":"ref_44","unstructured":"Agenzia Italiana del Farmaco (2021, August 02). Modifica delle Modalit\u00e0 di Impiego del Medicinale Mifegyne a Base di Mifepristone (RU486), Available online: https:\/\/www.aifa.gov.it\/documents\/20142\/1134592\/Determina_865-2020_MIFEGYNE-RU486.pdf\/884172c8-8b77-d938-4eda-6f9453be323a."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4081\/mem.2020.702","article-title":"RU486: \u00c8 solo una questione medico-farmacologica?","volume":"69","author":"Spagnolo","year":"2020","journal-title":"Med. E Morale"},{"key":"ref_46","unstructured":"International Federation of Gynecology and Obstetrics (2021, October 27). FIGO Endorses the Permanent Adoption of Telemedicine Abortion Services. Available online: https:\/\/www.figo.org\/FIGO-endorses-telemedicine-abortion-services."},{"key":"ref_47","unstructured":"(2021, August 03). Legge 22 dicembre 2017, n. 219. Norme in materia di consenso informato e di disposizioni anticipate di trattamento. Gazzetta Ufficiale della Repubblica Italiana Numero 12. Published 16 January 2018. Available online: https:\/\/www.gazzettaufficiale.it\/eli\/id\/2018\/1\/16\/18G00006\/sg."},{"key":"ref_48","unstructured":"Parlamento europeo (2021, August 02). Relazione sulla Situazione della Salute Sessuale e Riproduttiva e Relativi Diritti Nell\u2019UE, nel Quadro della Salute delle Donne. Available online: https:\/\/www.europarl.europa.eu\/doceo\/document\/A-9-2021-0169_IT.pdf."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/22\/12043\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:31:18Z","timestamp":1760167878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/22\/12043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":48,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["ijerph182212043"],"URL":"https:\/\/doi.org\/10.3390\/ijerph182212043","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,16]]}}}